{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-011398","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2022-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.512530+00:00","generated_at":"2026-06-27T11:44:45.307868+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Voyager Therapeutics appoints ex-Biogen EVP Alfred Sandrock to board, names Robin Swartz COO","bullets":["Alfred Sandrock, former Biogen EVP R&D, appointed to Board effective Feb 7, 2022; consulting agreement at $30k/month.","Robin Swartz promoted to COO; base salary $420k, target bonus 40%, and option grant of 65,000 shares.","Sandrock receives standard director compensation: $40k annual cash, initial option for 44,000 shares, plus committee fees.","Swartz's employment extends COBRA premium payments to 12 months on qualifying termination.","Both appointments effective Feb 7, 2022; Sandrock's term runs until 2023 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-011398","json":"https://secwatch.observer/filing/0001104659-22-011398.json","markdown":"https://secwatch.observer/filing/0001104659-22-011398.md","text":"https://secwatch.observer/filing/0001104659-22-011398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922011398/0001104659-22-011398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922011398/tm225066d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T11:44:45.307868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb47820277","claim":"Alfred Sandrock, M.D., Ph.D. was appointed as director at Voyager Therapeutics, Inc..","evidence_excerpt":"appointed Alfred Sandrock, M.D., Ph.D. as a director of the Company and as a member of both the Executive Committee and the Science and Technology Committee of the Board, effective February 7, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922011398/0001104659-22-011398-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}